ContraVir stock: buy or sell?

CTRV stock price: $2.93 -3.30% At close on July 25th, 2019

Updated on:
July 25th, 2019

0

After sliding a scary -5.61% on July, ContraVir closed on July at $2.93 and fell a godawful -3.30%. With July it's been 3 red days in a row.

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections.

Should I buy ContraVir stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Currently, ContraVir stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean CTRV will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is ContraVir stock a buy?

Financial institutions and banks post stock ratings everyday. At Stocks2.com, we found 1 rating published for CTRV stock in the last 30 days.

Is CTRV a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-3-20Maxim GroupBuyHold

ContraVir stock analysis

Daily outlook

After sliding a scary -5.61% on July, ContraVir closed on July at $2.93 and fell a godawful -3.30%.

After sliding a scary -5.61% on July, ContraVir closed on July at $2.93 and fell a godawful -3.30%. CTRV marked a lower low and a lower high in the short term, defining a downward trend. Climbing above $4.45 would break this short term down trend and open possibilities for reversing this situation. Since last April when CTRV stock price broke down the SMA50d line, it slid $-14.50 per share (-83.19%).

CTRV stock chart (daily)

Weekly outlook

ContraVir plummed a scary -17.70% this week. By mid June CTRV climbed a super good 10.24% in just one week.

Since price and 10-weeks moving average lines crossed down by mid June, CTRV fell $-5.96 per share (-67.04%).

CTRV stock chart (weekly)

ContraVir stock price history

ContraVir stock went public on February 20th, 2014 with a price of $840.001. Since then, CTRV stock declined a -99.70%, with a yearly average of -19.90%.

1: Adjusted price after possible price splits or reverse-splits.

ContraVir stock historical price chart

CTRV stock reached 52-week highs at $121.10, and all-time highs 2015-10-05 with a price of 3516.8.

ContraVir stock price target

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we have not found any price target for ContraVir stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

After posting its last earnings report on November, ContraVir . Unfortunately, reported EPS is not yet available in our database.
CTRV earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.12n/a
2017-Q2-n/a0.03n/a
2017-Q32017-10-27-0.07-0.08n/a
2017-Q42018-04-03n/an/an/a
2018-Q12018-05-15n/a-0.03n/a
2018-Q22018-08-14n/a-0.38n/a
2018-Q32018-11-14n/a-0.9n/a
2018-Q4-n/an/an/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In , ContraVir Pharmaceuticals annual revenues to million dollars from marked in . , its income margin (compared to revenues) to , that is million.

CTRV annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY

Quarterly financial results

Reported quarter earnings marked $-0.16 million with a profit margin of . Profit margin stayed stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, ContraVir Pharmaceuticals sales marked a neutral movement and remained constant a nan%. Looking back to recent quarterly results, ContraVir posted 2 positive quarters in a row.
CTRV quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2

ContraVir ownership

When you are planning to invest in shares of a stock, it's always worth to check its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For ContraVir, of all outstanding shares are owned by its staff.

For a better understanding, the next table shows ownership data compared to other related companies:

CTRV
Market cap$0.0 M
Total shares0.0 M
Float shares0.0 M
  - Institutional holdings (%)0.0%
  - Insider holdings (%)0.0%
Shares in short selling0.0%

ContraVir summary

Thursday, July 25th, 2019
Open$3.03
Close$2.93
Day range$2.80 - $3.15
Previous close$3.03
Session gain-3.30%
Average true range$0.34
50d mov avg$5.83
100d mov avg$10.36
200d mov avg$21.15
Daily patternlb06a
Weekly pattern lb06a

ContraVir performance

To measure stock performance is always good to benchmark with competitors or related stocks. We selected as the bechmarking frame for ContraVir Pharmaceuticals stock.
Stock3m6m12m
CTRVContraVir Pharmac...-61.95%-87.24%-95.40%

ContraVir competitors

Unfortunately, we could not find any public company that could be defined as ContraVir Pharmaceuticals competitor. This doesn't mean ContraVir Pharmaceuticals does not have any competitor in the market, it's just we could not detected it.